Lung clearance index in children with cystic fibrosis previously diagnosed with CRMS/CFSPID: A monocentric prospective experience

Pediatr Pulmonol. 2023 Jul;58(7):2124-2131. doi: 10.1002/ppul.26442. Epub 2023 May 3.

Abstract

Introduction: No data are available on the values and role of lung clearance index (LCI) in cystic fibrosis (CF) Screen Positive Inconclusive Diagnosis (CFSPID) progressed to CF diagnosis (CFSPID > CF). This study aimed to assess the value of the LCI in correctly predicting the progression of CFSPID to CF.

Methods: This is a prospective study carried out at the CF Regional Center of Florence, Italy from September 1, 2019. We compared LCI values in children with CF diagnosed for positive newborn screening (NBS), CFSPID or CFSPID > CF for pathological sweat chloride (SC). The Exhalyzer-D (EcoMedics AG, Duernten, Switzerland, software version 3.3.1) was used to conduct the LCI tests, every 6 months on stable children.

Results: Forty-two cooperating children were enrolled (mean age at LCI tests: 5.4 years, range: 2.7-8.7): 26 (62%) had CF, 8 (19%) were CFSPID > CF for positive SC, while 8 (19%) kept the CFSPID label at last LCI test. The mean LCI value for patients with CF (7.39; 5.98-10.24) was statistically higher compared to both the mean LCI in the CFSPID > CF (6.62; 5.69-7.58) and in CFSPID (6.56; 5.64-7.21).

Conclusions: Most of asymptomatic CFSPID or progressed to CF have normal LCI. Further data on the longitudinal course of LCI during follow up of CFSPID and on larger cohorts is needed.

Keywords: FEV1; LCI; inconclusive diagnosis; neonatal screening; sweat chloride.

MeSH terms

  • Child
  • Child, Preschool
  • Cystic Fibrosis Transmembrane Conductance Regulator
  • Cystic Fibrosis* / diagnosis
  • Humans
  • Infant, Newborn
  • Lung
  • Neonatal Screening
  • Prospective Studies

Substances

  • Cystic Fibrosis Transmembrane Conductance Regulator